Glenn Pierce on Overcoming Barriers to Gene Therapy in Hemophilia Care
“We published a reflective article on why the uptake of gene therapy in hemophilia is less than expected. It’s not due to lack of interest in gene therapy in general by patients and health care providers, as some have alleged, but related to more complex problems including the differing benefit/risk balance of individual gene therapies and need for more creative reimbursement frameworks. Medicines with strong efficacy and safety have been, and will continue to be embraced by the community. We look forward to advancing technological improvements in gene therapies, including gene editing, especially for hemophilia A, and to more enthusiasm of biopharma to reach 85% of the world having substandard or no treatment.”
To learn more, follow the link.
Read the full article here.
Article: Why is the uptake of gene therapy in hemophilia less than expected?
Authors:
Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar